BMS rush for avagacestat as it trends decline in the demented
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb is terminating development of avagacestat, a member of the troublesome gamma secretase inhibitor drug class, for the treatment of Alzheimer's disease.